Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children.

BACKGROUND AND AIM: We report here our experience of using pegylated granulocyte colony stimulating factor (peg-GCSF) for peripheral blood stem cell (PBSC) mobilization in children. METHODS AND RESULTS: A total of nine children suffering from high-risk/relapsed solid tumors were mobilized with chemotherapy and peg-GCSF (100 microgram/kg single dose). Mean age was 7.7 years (range 2-15 years).The mean time from peg-GCSF administration to PBSC harvest was 9.7 days. Adequate stem cells (median dose 26.9 million/kg) could be harvested in all children by a single apheresis procedure. No major adverse events observed. CONCLUSION: It is feasible and safe to mobilize PBSC with peg-GCSF in children with cancer.

Annatto-entrapped casein-chitosan complexes improve whey color quality after acid coagulation of milk.

A fraction of annatto is often transferred to the whey fluid during Cheddar cheese processing, which negatively impacts the visual and sensory attributes of the resultant whey powder. Alternatives to reduce the color in the powder are still needed. In this study, casein-chitosan complexes were prepared to deliver annatto preferentially to the curd and reduce the amount of carryover colorant in whey powder. These complexes were relatively spherical, with a mean complex diameter of 8.3 ±â€¯1.9 µm, zeta-potential of +39.4 ±â€¯1.3 mV, and entrapment efficiency of 38.2 ±â€¯3.1%. FT-IR spectroscopy confirmed the electrostatic interaction between casein and chitosan. Complexes and commercial annatto powder were incorporated into homogenized, reduced-fat, and fat-free milk, and subjected to acid coagulation. Whey powder produced from casein-chitosan-complex-treated samples exhibited better color quality than that prepared with annatto powder, indicating that the approach considered in this study was efficient in preventing the migration of colorant to the whey.

Formulation and optimization of topotecan nanoparticles: In vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes.

The study focuses on widening up the therapeutic perspective of anti-cancer therapy by entrapping a hydrophilic anticancer drug, topotecan hydrochloride (TOPO) in biodegradable poly (lactide-co-glycolide) (PLGA) matrix to form topotecan nanoparticles (TOPO NPs) by a double emulsion solvent evaporation technique. Statistical optimization using Box-Behnken design showed that sonication time of primary emulsion for 120 s, drug: polymer ratio of 1:12.65, organic phase: external aqueous phase ratio of 1:2.82 and 0.5% w/v of polyvinyl alcohol in the drug containing phase produced TOPO NPs with a size of 243.2 ±â€¯4 nm and an entrapment efficiency of 60.9 ±â€¯2.2%. TOPO NPs illustrated sustained release of TOPO for a week in phosphate buffer saline (PBS) at simulating physiological (pH 7.4) and acidic tumor microenvironmental (pH 6.5) conditions. A dramatic increase in cellular uptake with a corresponding enhanced cytotoxic potency was also displayed by TOPO NPs against human ovarian cancer cells (SKOV3) over time as compared to native drug, TOPO. These findings were further supported by the enhancement of bioavailability (13.05 fold) conferred by TOPO NPs from the in vivo pharmacokinetic study. The study represents a logistic approach for formulating TOPO NPs which can be used as an effective drug delivery system for the treatment of ovarian cancer.